Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Other Operating Expenses: 2023-2025

Historic Other Operating Expenses for Spyre Therapeutics (SYRE) over the last 1 years, with Jun 2025 value amounting to -$10.0 million.

  • Spyre Therapeutics' Other Operating Expenses was N/A to -$10.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $136.9 million, marking a year-over-year change of. This contributed to the annual value of $16.4 million for FY2023, which is N/A change from last year.
  • As of Q2 2025, Spyre Therapeutics' Other Operating Expenses stood at -$10.0 million, which was down 643.48% from $1.8 million recorded in Q4 2023.
  • Over the past 5 years, Spyre Therapeutics' Other Operating Expenses peaked at $130.5 million during Q2 2023, and registered a low of -$10.0 million during Q2 2025.
  • For the 2-year period, Spyre Therapeutics' Other Operating Expenses averaged around $34.2 million, with its median value being $8.2 million (2023).